These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7640054)

  • 1. Comparison of continuous infusion and bolus administration of ifosfamide in children.
    Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
    Eur J Cancer; 1995; 31A(5):785-90. PubMed ID: 7640054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
    Boddy AV; English M; Pearson AD; Idle JR; Skinner R
    Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.
    Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
    Cancer Chemother Pharmacol; 1996; 38(2):147-54. PubMed ID: 8616905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
    Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
    Cancer Res; 1993 Aug; 53(16):3758-64. PubMed ID: 8339288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
    Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
    Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.
    Boddy AV; Cole M; Pearson AD; Idle JR
    Cancer Chemother Pharmacol; 1995; 36(1):53-60. PubMed ID: 7720176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols].
    Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
    Klin Padiatr; 1992; 204(4):299-305. PubMed ID: 1518269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients.
    Cerny T; Küpfer A; Zeugin T; Brunner KW
    Ann Oncol; 1990 Sep; 1(5):365-8. PubMed ID: 2124500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.
    Calinski DM; Zhang H; Ludeman S; Dolan ME; Hollenberg PF
    Drug Metab Dispos; 2015 Jul; 43(7):1084-90. PubMed ID: 25934575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.
    Cerny T; Graf A; Rohner P; Zeugin T; Brunner KW; Küpfer A
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S129-34. PubMed ID: 1795001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
    Skubitz KM; Hamdan H; Thompson RC
    Cancer; 1993 Nov; 72(10):2963-9. PubMed ID: 8221562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients.
    Boddy AV; Proctor M; Simmonds D; Lind MJ; Idle JR
    Eur J Cancer; 1995; 31A(1):69-76. PubMed ID: 7695982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose finding of ifosfamide administered with a chronic two-week continuous infusion.
    Cartei G; Clocchiatti L; Sacco C; Pella N; Bearz A; Mantero J; Pastorelli D; Salmaso F; Zustovich F
    Oncology; 2003; 65 Suppl 2():31-6. PubMed ID: 14586144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma.
    Meazza C; Casanova M; Luksch R; Podda M; Favini F; Cefalo G; Massimino M; Ferrari A
    Pediatr Blood Cancer; 2010 Oct; 55(4):617-20. PubMed ID: 20589638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide enantiomers: pharmacokinetics in children.
    Prasad VK; Corlett SA; Abaasi K; Heney D; Lewis I; Chrystyn H
    Cancer Chemother Pharmacol; 1994; 34(5):447-9. PubMed ID: 8070015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.
    Singer JM; Hartley JM; Brennan C; Nicholson PW; Souhami RL
    Br J Cancer; 1998 Mar; 77(6):978-84. PubMed ID: 9528844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.
    Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
    Cancer Chemother Pharmacol; 1991; 28(6):455-60. PubMed ID: 1934249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules.
    Serrone L; Zeuli M; Papaldo P; Nardoni C; Pacetti U; Cognetti F
    Onkologie; 2001 Oct; 24(5):465-8. PubMed ID: 11694773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
    Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
    Baranzelli MC; Pichon F; Gourmel B; N'Guyen M; Deligny N; Demaille MC
    Bull Cancer; 1997 Feb; 84(2):141-6. PubMed ID: 9180836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.